Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results